{"entity":{"id":"paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020","kind":"paper","name":"TROPHIMMUN cohort A: avelumab in gestational trophoblastic tumours resistant to single-agent chemotherapy","aka":[],"tldr":"The PD-L1 antibody avelumab cured about half of women whose gestational trophoblastic tumour had stopped responding to single-drug chemotherapy, with mild side effects.","summary":"Single-arm phase 2 trial at the Hospices Civils de Lyon: 15 women with gestational trophoblastic tumours resistant to methotrexate (all) or actinomycin D received avelumab 10 mg/kg every two weeks until hCG normalised and for three further cycles.\n\nEight women (53.3 percent) reached normal hCG after a median of nine cycles and none relapsed at a median follow-up of 25 months; one later had a healthy pregnancy. Grade 1 to 2 treatment-related adverse events occurred in 93 percent (fatigue, nausea or vomiting, infusion reactions); the seven non-responders were cured with actinomycin D or combination chemotherapy and surgery.","asOf":"2026-09-22","links":[{"label":"J Clin Oncol 2020","url":"https://doi.org/10.1200/JCO.20.00803"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32716740/"}],"tags":[],"related":[],"cancers":["low-risk-gtn","gestational-trophoblastic"],"sections":[],"technologies":[],"targets":[],"drugs":["avelumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["trophimmun"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2020,"doi":"10.1200/JCO.20.00803","pmid":"32716740","authors":"You B, Bolze PA, Lotz JP, et al.","paperType":"observational","findings":["hCG normalisation in 8 of 15 women (53.3 percent) after a median of 9 cycles; no subsequent relapse.","Grade 1 to 2 treatment-related adverse events in 93 percent; one unrelated grade 3 uterine bleed."],"whatItMeans":"Avelumab is a chemotherapy-sparing option for single-agent-resistant gestational trophoblastic neoplasia, particularly where the alternative is combination chemotherapy.","caveats":["Fifteen patients; cohort B later showed little activity after combination chemotherapy failure."],"changedPractice":true,"participants":15},"route":"/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020/","neighbours":{"cancer":[{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/"}],"drug":[{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"}],"trial":[{"id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}